Home / Pipeline / Bendamustine 90 mg/m2 IV on Days 1-2, Cycles 1-6 Products Bendamustine 90 mg/m2 IV on Days 1-2, Cycles 1-6
Bendamustine 90 mg/m2 IV on Days 1-2, Cycles 1-6 Phase 2 UNKNOWN 💤 Quiet Interest: 31/100
Diffuse Large B Cell Lymphoma
Diffuse Large B Cell Lymphoma, Primary Mediastinal (Thymic) Large B-cell Lymphoma, Transformed Indolent Lymphoma, Recurrent Disease, Refractory Cancer
Dec 1, 2016 → Oct 1, 2021
About Bendamustine 90 mg/m2 IV on Days 1-2, Cycles 1-6 Bendamustine 90 mg/m2 IV on Days 1-2, Cycles 1-6 is a phase 2 stage product being developed by Johnson & Johnson for Diffuse Large B Cell Lymphoma. The current trial status is unknown. This product is registered under clinical trial identifier NCT02747732. Target conditions include Diffuse Large B Cell Lymphoma, Primary Mediastinal (Thymic) Large B-cell Lymphoma, Transformed Indolent Lymphoma.
What happened to similar drugs? 1 of 20 similar drugs in Diffuse Large B Cell Lymphoma were approved
Clinical Trials (1) NCT ID Phase Status Start Completion Indication NCT02747732 Phase 2 UNKNOWN Dec 1, 2016 Oct 1, 2021 Diffuse Large B Cell Lymphoma
Product Company Stage Hype Score IVA337 + Placebo Inventiva Phase 2 Gemcitabine-Oxaliplatin plus Rituximab (R-GEMOX) Eli Lilly Phase 2 rituximab Celltrion Phase 1 YM155 Astellas Pharma Phase 2 enzastaurin + gemcitabine + rituximab + oxaliplatin Eli Lilly Phase 2 VELCADE + Rituximab + Cyclophosphamide + Doxorubicin + Prednisone + Vincristine Johnson & Johnson Phase 2 Epcoritamab + Rituximab + Lenalidomide + Oxaliplatin + Gemcitabine AbbVie Phase 3 ABBV-525 AbbVie Phase 1 rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone + rituximab and lenalidomide + rituximab and bendamustine + rituximab, cytarabine, dexamethasone, and oxaliplatin/carboplatin + gemcitabine and oxaliplatin + Epcoritamab + rituximab, cyclophosphamide, reduced dose of doxorubicin, vincristine, and prednisone + Lenalidomide + rituximab, ifosfamide, carboplatin, and etoposide phosphate + Epcoritamab + Epcoritamab + Epcoritamab + Epcoritamab + Epcoritamab + Epcoritamab + Epcoritamab + Rituximab and Lenalidomide + Epcoritamab AbbVie Phase 1/2 Copanlisib + Venetoclax AbbVie Phase 1/2 Epcoritamab + Investigator's Choice Chemotherapy AbbVie Phase 3 Epcoritamab + Lenalidomide AbbVie Phase 2 Venetoclax + Selinexor AbbVie Phase 1 Epcoritamab AbbVie Phase 1 Loncastuximab Tesirine and Epcoritamab AbbVie Phase 2 Epcoritamab + Investigator's Choice Chemotherapy AbbVie Phase 3 bendamustine + navitoclax + rituximab AbbVie Phase 2 Epcoritamab AbbVie Phase 2 Epcoritamab (monotherapy) + Epcoritamab + Rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone + Gemcitabine and oxaliplatin + Epcoritamab (maintenance) + Rituximab and lenalidomide AbbVie Phase 1/2 Epcoritamab + Ibrutinib AbbVie Phase 1/2